ArticleEmerging infectious diseases2021
Estimating the Force of Infection for Dengue Virus Using Repeated Serosurveys, Ouagadougou, Burkina Faso.
Article in Emerging infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Dengue and chikungunya virus transmission in Kinshasa, Democratic Republic of the Congo.medRxiv : the preprint server for health sciences · 2026Article
- Seroprevalence of dengue virus infection and associated risk factors: a community-based cross-sectional survey in Burkina Faso.BMJ public health · 2026Article
- [Clinical aspects of dengue fever in the Savanna region of Togo in 2023].Medecine tropicale et sante internationale · 2025Article
- Serologic Evidence of Circulation of Six Arboviruses (Dengue Virus, Chikungunya Virus, Zika Virus, Rift Valley Virus, Yellow Fever Virus, Crimean-Congo Hemorrhagic Fever Virus) in Four Regions of Burkina Faso, West Africa.Tropical medicine and infectious disease · 2025Article
- Force of Infection Model for Estimating Time to Dengue Virus Seropositivity among Expatriate Populations, Thailand.Emerging infectious diseases · 2025Article
- Estimating Dengue Outbreak Thresholds in West Africa: A Comprehensive Analysis of Climatic Influences in Burkina Faso, 2018-2024.Tropical medicine and infectious disease · 2025Article
- Dynamics of SARS-CoV-2 infection over two epidemic waves in Manaus, Brazil: A serological study of seven thousand blood donors.PloS one · 2025Article
- From serological surveys to disease burden: a modelling pipeline for Chagas disease.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023Article
- Seroprevalence of Dengue and Chikungunya Virus Infections in Children Living in Sub-Saharan Africa: Systematic Review and Meta-Analysis.Children (Basel, Switzerland) · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Because of limited data on dengue virus in Burkina Faso, we conducted 4 consecutive age-stratified longitudinal serologic surveys, ≈6 months apart, among persons 1-55 years of age, during June 2015-March 2017, which included a 2016 outbreak. The seroconversion rate before the serosurvey enrollment was estimated by binomial regression, taking age as the duration of exposure, and assuming constant force of infection (FOI) over age and calendar time. We calculated FOI between consecutive surveys and rate ratios for potentially associated characteristics based on seroconversion using the duration of intervals. Among 2,897 persons at enrollment, 66.3% were IgG-positive, and estimated annual FOI was 5.95%. Of 1,269 enrollees participating in all 4 serosurveys, 438 were IgG-negative at enrollment. The annualized FOI ranged from 10% to 20% (during the 2016 outbreak). Overall, we observed high FOI for dengue. These results could support decision-making about control and preventive measures for dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.